CD133 expression in circulating hematopoietic progenitor cells

Abstract

Background: Circulating hematopoietic progenitors (HPCs) have been implicated in inflammatory diseases such as atherosclerosis, and in repair and regeneration of damaged tissue after injury. Recently published studies suggest the levels of blood borne HPCs in human subjects may represent a useful biomarker to predict future cardiovascular disease (CVD) events. These studies have indicated an age and CVD risk factor dependent relationship between HPC levels and future risk of CVD events. CD133 expression within the circulating CD34+ HPC pool has been used to identify a subpopulation of CD34+ cells enriched for progenitor cells. Our goal was to determine the distribution of CD133 expression within HPC sub-types amongst circulating CD34+ cells. Methods: The quantity of different HPC populations within the CD34+ CD133+ and CD34+ CD133− fractions of venous blood obtained from healthy human subjects was measured using multi-color flow cytometry. Results: The majority of circulating CD34+ cells are CD133−. CD133+ CD34+ cells express low levels of CD38, contain cell populations bearing cell surface markers of hematopoietic stem cells, multi potent progenitors, and multi lymphoid progenitors, and are largely devoid of CD38 expressing lineage specified progenitors. These findings clarify the composition of circulating CD133+ CD34+ cell types cited in epidemiological studies of CVD and other diseases.

From the Editor: Thank you! Remembrances and Issue Highlights

“…CD34 expression is variously useful both in clinical diagnostics and cellular therapy. The contribution by Cimato et al (15), looks at the CD34+ pool of circulating hematopoietic progenitor cells obtained from six healthy donors and quantitates and assesses the subpopulation of prominin-1 / CD133+ cells within it. We learn that the CD133+ subset, that is about a third of circulating CD34+ cells, express virtually no CD38 and contain cells that are primarily functionally stem cells and multipotent progenitors.…”

Human CD133-positive hematopoietic progenitor cells enhance the malignancy of breast cancer cells

“…HPCs can proliferate and differentiate into various kinds of blood cells. Human HPCs can be recognized by their surface CD133 and CD34 expression [9][10][11][12][13]. The early developing human CD133+ HPCs are a subpopulation of cells in the bone marrow, fetal liver, UCB and peripheral blood [14][15][16][17][18].…”

Human CD133-positive hematopoietic progenitor cells enhance the malignancy of breast cancer cells

“…HPCs can proliferate and differentiate into various kinds of blood cells. Human HPCs can be recognized by their surface CD133 and CD34 expression [9][10][11][12][13]. The early developing human CD133+ HPCs are a subpopulation of cells in the bone marrow, fetal liver, UCB and peripheral blood [14][15][16][17][18].…”